Treatment of hemophilia B: focus on recombinant factor IX

eatment of hemophilia B: focus on recombinant factor IX Review (751) Total Article Views Authors: Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C Published Date February 2013 Volume 2013:7 Pages 33 - 38 DOI: http://dx.doi.org/10.2147/BTT.S31582 Received: 19 December 2012 Accepted: 16 January 2013 Published: 12 February 2013 Massimo Franchini, Francesco Frattini, Silvia Crestani, Cinzia Sissa, Carlo Bonfanti Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy Abstract: Hemophilia B is a recessive X-linked bleeding disorder characterized by deficiency of the coagulation factor IX (FIX). In hemophilia B patients the severity of the bleeding phenotype is related to the degree of the FIX defect. Hemophilia B treatment has improved greatly in the last 20 years with the introduction first of plasma-derived and then of recombinant FIX concentrates. Replacement therapy may be administered through on-demand or prophylaxis regimens, but the latter treatment modality has been shown to be superior in prevention of hemophilic arthropathy and in improvement of patients' quality of life. The purpose of this narrative review is to summarize the current knowledge on treatment strategies for hemophilia B, focusing on recombinant FIX products either clinically used or in development. There is only one rFIX product that is licensed to treat hemophilia B patients; from the analysis of the literature data presented in this review, the authors conclude that this rFIX product has demonstrated an excellent safety profile and excellent clinical efficacy for halting and preventing bleeds in hemophilia B patients. While prophylaxis has emerged as the best therapeutic strategy for such patients because of its ability to prevent hemophilic arthropathy and to improve patients' quality of life, the pharmacokinetically tailored dosing of rFIX is another key point when planning hemophilia B treatment, as it allows optimization of the factor concentrate usage. Further clinical studies are needed to better assess the safety and efficacy (ie, the incidence of adverse reactions and inhibitor development) of newer rFIX products.